These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 16932551

  • 21. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T.
    Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322
    [Abstract] [Full Text] [Related]

  • 22. New insights into adaptive immunity in chronic neuroinflammation.
    Siffrin V, Brandt AU, Herz J, Zipp F.
    Adv Immunol; 2007 Apr; 96():1-40. PubMed ID: 17981203
    [Abstract] [Full Text] [Related]

  • 23. Antigen-specific therapies in multiple sclerosis.
    Sospedra M, Martin R.
    Int Rev Immunol; 2005 Apr; 24(5-6):393-413. PubMed ID: 16318988
    [Abstract] [Full Text] [Related]

  • 24. [Pathogenesis of multiple sclerosis and other neural autoimmune diseases].
    Lassmann H.
    Verh Dtsch Ges Pathol; 1996 Apr; 80():109-15. PubMed ID: 9064993
    [Abstract] [Full Text] [Related]

  • 25. [Multiple sclerosis: epidemiology, molecular pathology and therapy].
    Steck AJ, Schaeren-Wiemers N.
    Schweiz Med Wochenschr; 1999 Nov 20; 129(46):1764-8. PubMed ID: 10603650
    [Abstract] [Full Text] [Related]

  • 26. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation.
    Zozulya AL, Wiendl H.
    Hum Immunol; 2008 Nov 20; 69(11):797-804. PubMed ID: 18723060
    [Abstract] [Full Text] [Related]

  • 27. The role of immune semaphorins in multiple sclerosis.
    Okuno T, Nakatsuji Y, Kumanogoh A.
    FEBS Lett; 2011 Dec 01; 585(23):3829-35. PubMed ID: 21420960
    [Abstract] [Full Text] [Related]

  • 28. EAE: imperfect but useful models of multiple sclerosis.
    't Hart BA, Gran B, Weissert R.
    Trends Mol Med; 2011 Mar 01; 17(3):119-25. PubMed ID: 21251877
    [Abstract] [Full Text] [Related]

  • 29. Immunotherapeutic approaches in multiple sclerosis.
    Adorini L.
    J Neurol Sci; 2004 Aug 15; 223(1):13-24. PubMed ID: 15261555
    [Abstract] [Full Text] [Related]

  • 30. The pathology of multiple sclerosis and its evolution.
    Lassmann H.
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct 29; 354(1390):1635-40. PubMed ID: 10603616
    [Abstract] [Full Text] [Related]

  • 31. Immune tolerance and control of CNS autoimmunity: from animal models to MS patients.
    Cassan C, Liblau RS.
    J Neurochem; 2007 Feb 29; 100(4):883-92. PubMed ID: 17181557
    [Abstract] [Full Text] [Related]

  • 32. Immunopathogenesis of multiple sclerosis.
    Comabella M, Khoury SJ.
    Clin Immunol; 2012 Jan 29; 142(1):2-8. PubMed ID: 21458377
    [Abstract] [Full Text] [Related]

  • 33. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P, Garren H, Steinman L.
    Int Rev Immunol; 2005 Jan 29; 24(5-6):415-46. PubMed ID: 16318989
    [Abstract] [Full Text] [Related]

  • 34. [Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].
    Svenningsson A, Andersson M, Olsson T.
    Lakartidningen; 1998 Dec 02; 95(49):5631-5. PubMed ID: 9863301
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Interferon-beta mechanisms of action in multiple sclerosis.
    Dhib-Jalbut S, Marks S.
    Neurology; 2010 Jan 05; 74 Suppl 1():S17-24. PubMed ID: 20038758
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. New directions in MS therapeutics: vehicles of hope.
    Fox RJ, Ransohoff RM.
    Trends Immunol; 2004 Dec 05; 25(12):632-6. PubMed ID: 15530830
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.